Skip to main navigation Skip to search Skip to main content

High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment in High-Risk Breast Cancer: Data from the European Group for Blood and Marrow Transplantation Registry

  • Massimo Martino*
  • , Francesco Lanza
  • , Lorenzo Pavesi
  • , Mustafa Ozturk
  • , Didier Blaise
  • , Ruben Leno Nunez
  • , Hendricus Schouten
  • , Alberto Bosi
  • , Ugo De Giorgi
  • , Daniele Generali
  • , Giovanni Rosti
  • , Andrea Necchi
  • , Andrea Ravelli
  • , Carmelo Bengala
  • , Manuela Badoglio
  • , Paolo Pedrazzoli
  • , Marco Bregni
  • *Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

The aim of this retrospective study was to assess toxicity and efficacy of adjuvant high-dose chemotherapy (HDC) and autologous hematopoietic stem cell transplantation (AHSCT) in 583 high-risk breast cancer (BC) patients (>3 positive nodes) who were transplanted between 1995 and 2005 in Europe. All patients received surgery before transplant, and 55 patients (9.5%) received neoadjuvant treatment before surgery. Median age was 47.1 years, 57.3% of patients were premenopausal at treatment, 56.5% had endocrine-responsive tumors, 19.5% had a human epidermal growth factor receptor 2 (HER2)-negative tumor, and 72.4% had >= 10 positive lymph nodes at surgery. Seventy-nine percent received a single HDC procedure. Overall transplant-related mortality was 1.9%, at .9% between 2001 and 2005, whereas secondary tumor-related mortality was .9%. With a median follow-up of 120 months, overall survival and disease-free survival rates at 5 and 10 years in the whole population were 75% and 64% and 58% and 44%, respectively. Subgroup analysis demonstrated that rates of overall survival were significantly better in patients with endocrine-responsive tumors,
Original languageEnglish
Pages (from-to)475-481
Number of pages7
JournalBiology of Blood and Marrow Transplantation
Volume22
Issue number3
DOIs
Publication statusPublished - Mar 2016

Keywords

  • Autologous hematopoietic stem cell transplantation
  • High-dose chemotherapy
  • High-risk breast cancer

Fingerprint

Dive into the research topics of 'High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment in High-Risk Breast Cancer: Data from the European Group for Blood and Marrow Transplantation Registry'. Together they form a unique fingerprint.

Cite this